Abstract
Children with problematic asthma represent about 0.5% of the population but consume a disproportionate amount of healthcare staff time and resources. The most important step in managing children with problematic asthma is differentiating those with genuine severe, therapy resistant disease from those who have difficult to treat asthma for a variety of other remediable factors. The most common causes of poor symptom control are poor adherence to therapy, ongoing exposure to sensitized allergens or co-morbid psychosocial problems. In up to half of the children with problematic asthma, addressing these simple factors can avoid further escalation of treatment or more invasive investigation. All asthmatic children with poor control despite treatment with ≥ 800μg of inhaled budesonide (or equivalent) should be referred to a paediatric respiratory specialist for evaluation. Management of children with problematic asthma, and particularly those with genuine severe therapy resistant disease, requires a stepwise multidisciplinary approach.
Keywords: Asthma, problematic, severe, difficult, adherence, steroid-sparing
Current Pediatric Reviews
Title: Severe Asthma: Why do Some Children Not Respond to Treatment?
Volume: 6 Issue: 2
Author(s): Ruth O'Reilly and Sejal Saglani
Affiliation:
Keywords: Asthma, problematic, severe, difficult, adherence, steroid-sparing
Abstract: Children with problematic asthma represent about 0.5% of the population but consume a disproportionate amount of healthcare staff time and resources. The most important step in managing children with problematic asthma is differentiating those with genuine severe, therapy resistant disease from those who have difficult to treat asthma for a variety of other remediable factors. The most common causes of poor symptom control are poor adherence to therapy, ongoing exposure to sensitized allergens or co-morbid psychosocial problems. In up to half of the children with problematic asthma, addressing these simple factors can avoid further escalation of treatment or more invasive investigation. All asthmatic children with poor control despite treatment with ≥ 800μg of inhaled budesonide (or equivalent) should be referred to a paediatric respiratory specialist for evaluation. Management of children with problematic asthma, and particularly those with genuine severe therapy resistant disease, requires a stepwise multidisciplinary approach.
Export Options
About this article
Cite this article as:
O'Reilly Ruth and Saglani Sejal, Severe Asthma: Why do Some Children Not Respond to Treatment?, Current Pediatric Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339610791561150
DOI https://dx.doi.org/10.2174/157339610791561150 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
How Insulin Receptor Substrate Proteins Regulate the Metabolic Capacity of the Liver - Implications for Health and Disease
Current Medicinal Chemistry Small Heat Shock Proteins and the Endoplasmic Reticulum: Potential Attractive Therapeutic Targets?
Current Molecular Medicine The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology Mechanisms and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Agonists and Antagonists of Protease Activated Receptors (PARs)
Current Medicinal Chemistry Cationic Polymer Optimization for Efficient Gene Delivery
Mini-Reviews in Medicinal Chemistry Oxidative Stress as a Key Signaling Pathway in Placental Angiogenesis Changes in Preeclampsia: Updates in Pathogenesis, Novel Biomarkers and Therapeutics
Current Pharmacogenomics and Personalized Medicine Developments of DNA-dependent Protein Kinase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Flavonoids in Neurodegeneration: Limitations and Strategies to Cross CNS Barriers
Current Medicinal Chemistry p53: A Guide to Apoptosis
Current Cancer Drug Targets Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye
Current Medicinal Chemistry Novel Pentablock Copolymer Based Nanoparticles Containing Pazopanib: A Potential Therapy for Ocular Neovascularization
Recent Patents on Nanomedicine Glucocorticoid Regulates Parkin Expression in Mouse Frontal Cortex: Implications in Schizophrenia
Current Neuropharmacology Polyphenols and Cardiovascular Disease: A Critical Summary of the Evidence
Mini-Reviews in Medicinal Chemistry Targeting DNA Associated Processes for Cancer Therapy by the Use of SELEX and Anti-gene Approaches - When Selection Meets Rational Design
Medicinal Chemistry Reviews - Online (Discontinued) Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Osteoprotegerin Positively Regulates Hematopoietic Progenitor Cells
Current Stem Cell Research & Therapy Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology Therapeutic Potentials of Recently Identified PLD Inhibitors
Current Chemical Biology